

# Special Issue

## Antibacterial Drug Discovery

### Message from the Guest Editor

The emergence of multidrug resistant and extensively drug resistant bacteria, in particular of the so-called ESKAPE pathogens, urges the development of novel and innovative therapeutic approaches. Despite the antibiotic crisis rises, only one antibiotic with a novel mechanism of action has been approved in the last two decades. Although many innovative strategies to combat bacterial infections have been developed and resulted in promising bioactive substances, most drugs in clinical trials are still based on modifications of already approved drugs. In order to highlight the recent advances in the fight against bacterial infections, this special issue seeks manuscript submissions from all areas of antibacterial drug discovery. Topics may cover the discovery and validation of novel drug targets in pathogenic Gram-positive and Gram-negative bacteria, the identification of antibacterial compounds (small molecules, natural products, peptides and peptidomimetics, nanoparticles, and others) or adjuvants, assessments of treatment combinations, or the development of novel techniques and assays that support antibacterial drug discovery.

---

### Guest Editor

Dr. Björn Windshügel

Fraunhofer Institute for Molecular Biology and Applied Ecology IME,  
ScreeningPort, Hamburg, Germany

---

### Deadline for manuscript submissions

closed (31 December 2020)



## Antibiotics

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.5  
CiteScore 10.2  
Indexed in PubMed



[mdpi.com/si/39390](https://mdpi.com/si/39390)

*Antibiotics*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[antibiotics@mdpi.com](mailto:antibiotics@mdpi.com)

[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)





# Antibiotics

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.5  
CiteScore 10.2  
Indexed in PubMed



[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)



## About the Journal

### Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

---

### Editor-in-Chief

Prof. Dr. Nicholas Dixon  
School of Chemistry and Molecular Bioscience, University of  
Wollongong, Wollongong, NSW 2522, Australia

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)